Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension

Current Therapeutic Research - Clinical and Experimental

Volumn 65, Issue 3, 2004, Pages 239-254

  Branchi, Adriana ^a   Fiorenza, Anna Maria ^b   Torri, Adriana ^b   Berra, Cristina ^b   Colombo, Emanuela ^b   Rovellini, Angelo ^a   Sommariva, Domenico ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b RHO HOSPITAL   (Italy)

Author keywords

blood pressure; hypercholesterolemia; simvastatin

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CREATINE KINASE; DIGOXIN; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PROPAFENONE; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; LIPID BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 5444244233     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(04)80057-2     Document Type: Article

References (32)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
3. Vogel RA, Corretti MC, and Plotnick GD Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men Am J Cardiol 77 1996 37 40
4. O'Driscoll G, Green D, and Taylor RR Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month Circulation 95 1997 1126 1131
5. Laufs U, La Fata V, Plutzky J, and Liao JK Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
6. Tonolo G, Melis MG, and Formato M Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients EurJ Clin Invest 30 2000 980 987
7. Antonicelli R, Onorato G, and Pagelli P Simvastatin in the treatment of hypercholesterolemia in elderly patients Clin Ther 12 1990 165 171
8. Sartor G, Katzman P, and Eizyk E Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus Int J Clin Pharmacol Ther 33 1995 3 6
9. Guidelines Subcommittee 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension J Hypertens 17 1999 151 183
10. National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circulation 89 1994 1333 1445
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
12. Allain CC, Poon LS, and Chan CS Enzymatic determination of total serum cholesterol Clin Chem 20 1974 470 475
13. Bucolo G, and David H Quantitative determination of serum triglycerides by use of enzymes Clin Chem 19 1973 476 482
14. Friedewald WT, Levy RI, and Fredrickson DS Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
15. Sever PS, Dahlof B, Poulter NR for the ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multi-centre randomised controlled trial Lancet 361 2003 1149 1158
16. [in Hungarian] Jarai Z, Kapocsi J, and Farsang C Effect of fluvastatin on serum lipid levels in essential hypertension Orv Hetil 137 1996 1857 1859
17. [in French] Abetel G, Poget PN, and Bonnabry JP Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): A pilot study Schweiz Med Wochenschr 128 1998 272 277
18. Glorioso N, Troffa C, and Filigheddu F Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia Hypertension 34 1999 1281 1286
19. Ferrier KE, Muhlmann MH, and Baguet JP Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension J Am Coll Cardiol 39 2002 1020 1025
20. Borghi C, Prandin MG, and Costa FV Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia J Cardiovasc Pharmacol 35 2000 549 555
21. Sposito AC, Mansur AP, and Coelho OR Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hyper-cholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril) Am J Cardiol 83 A8 1999 1497 1499
22. D'Agostino RB, Kannel WB, Stepanians MN, and D'Agostino LC Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension Am J Cardiol 71 1993 82 87
23. O'Callaghan CJ, Krum H, and Conway EL Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients Blood Press 3 1994 404 406
24. Borghi C, Dormi A, and Veronesi M Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension J Clin Hypertens (Greenwich) 4 2002 277 285
25. Kaesemeyer WH, Caldwell RB, Huang J, and Caldwell RW Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions J Am Coll Cardiol 33 1999 234 241
26. Hernandez-Perera O, Perez-Sala D, and Navarro-Antolin J Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 1998 2711 2719
27. 1 receptor function and density in hypercholesterolemic men Circulation 100 1999 2131 2134
28. Ide H, Fujiya S, Aanuma Y, and Agishi Y Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones Clin Ther 12 1990 410 420
29. Rise P, Pazzucconi F, Sirtori CR, and Galli C Statins enhance arachidonic acid synthesis in hypercholesterolemic patients NutrMetab Cardiovasc Dis 11 2001 88 94
30. Kool M, Lustermans F, and Kragten H Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 48 1995 217 223
31. Muramatsu J, Kobayashi A, Hasegawa N, and Yokouchi S Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin Atherosclerosis 130 1997 179 182
32. Baldassarre D, Busnach G, and Amato M Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients Nutr Metab Cardiovasc Dis 9 1999 108 117